文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

靶向HER2过表达晚期实体瘤的CAR巨噬细胞疗法:一项1期试验

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.
PubMed 文献 · Nat Med · 2025-02-07

这项首次人体1期试验用抗HER2 CAR巨噬细胞CT-0508治疗14例HER2过表达晚期实体瘤患者,采用两种方案且不清除淋巴细胞。未观察到剂量限制性毒性、≥3级细胞因子释放综合征或免疫效应细胞相关神经毒性综合征;HER2 3+肿瘤中44%(9例中4例,95%CI 14-79%)在治疗后8周最佳总体疗效为疾病稳定,HER2 2+人群(5例)未见有意义的活性。

要点

  • CT-0508在HER2过表达晚期实体瘤中未观察到剂量限制性毒性。
  • 未观察到≥3级细胞因子释放综合征或免疫效应细胞相关神经毒性综合征。
  • HER2 3+肿瘤44%(9例中4例,95%CI 14-79%)达疾病稳定,HER2 2+人群(5例)未见有意义的活性。

核心结论

  • CT-0508在HER2+肿瘤中显示出初步的安全性、耐受性和生产可行性。

研究设计与样本

  • 首次人体1期临床试验,报告非预设中期分析结果,共治疗14例晚期HER2过表达肿瘤患者,采用两种不同方案。
  • 入组以乳腺癌和胃食管癌患者为主,须符合美国临床肿瘤学会/美国病理学家学会指南的HER2过表达(免疫组化3+或免疫组化2+/原位杂交扩增)。
  • 输注前未使用淋巴细胞清除化疗;主要终点为安全性和CAR-M可生产性,次要终点包括细胞动力学及客观缓解率、总生存期、无进展生存期和缓解持续时间等疗效指标。

主要发现

  • 未观察到剂量限制性毒性、严重细胞因子释放综合征(≥3级)或免疫效应细胞相关神经毒性综合征。
  • HER2 3+肿瘤中44%(9例中4例,95%置信区间=14-79%)在治疗后8周最佳总体疗效为疾病稳定。
  • HER2 2+人群(5例)中未观察到有意义的活性。
  • 连续活检的相关分析证实CT-0508迁移至并重塑肿瘤微环境,导致CD8+ T细胞扩增。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) macrophages (CAR-Ms) mediate antitumor immunity via phagocytosis, cytokine release, activation of the tumor microenvironment and antigen presentation. We report results from a non-prespecified interim analysis of a first-in-human, phase 1 clinical trial of CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) CAR-M in patients with advanced HER2-overexpressing tumors. Fourteen patients were treated across two different regimens. Patients with breast cancer and gastroesophageal cancer were primarily enrolled and had to have demonstrated overexpression of HER2 according to the American Society of Clinical Oncology/College of American Pathologists guidelines (HER2 immunohistochemistry 3+ or immunohistochemistry 2+/in situ hybridization-amplified). No lymphodepletion chemotherapy was used before infusion. The primary endpoints were safety and CAR-M manufacturability. Secondary endpoints included cellular kinetics and efficacy using objective response rate, overall survival, progression-free survival and duration of response. No dose-limiting toxicities, severe cytokine release syndrome (≥grade 3) or immune effector cell-associated neurotoxicity syndrome were observed; 44% (n = 4 of 9, 95% confidence interval = 14-79%) of HER2 3+ tumors achieved stable disease as best overall response 8 weeks after treatment. No meaningful activity was observed in the HER2 2+ population (n = 5). Correlative analyses of serial biopsies confirmed that CT-0508 traffics to and remodels the tumor microenvironment, resulting in expansion of CD8+ T cells. These findings demonstrate the preliminary safety, tolerability and manufacturing feasibility of CT-0508 for HER2+ tumors. ClinicalTrials.gov registration: NCT04660929 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Reiss KA, Angelos MG, Dees EC, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025. PMID: 39920391. doi:10.1038/s41591-025-03495-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。